On October 17, Director Huang Guo of the China Drug Administration met with Hong Kong Medical and Health Bureau Secretary Lu Chongmao and Director of Health Lam Man-kin and his entourage in Beijing. The two sides had in-depth exchanges on topics such as further strengthening cooperation between the Mainland and Hong Kong in drug supervision and supporting Hong Kong's drug regulatory capacity building. Lo Chung-mau said that the Hong Kong Drug Supervisory Authority is promoting the implementation of the Hong Kong Special Administrative Region's first five-year plan, comprehensively deepening pharmaceutical supervision reform, and will maintain close communication with the China Drug Administration in the future to help the high-quality development of the pharmaceutical industry. Lin Wenjian explained the situation of the upcoming Hong Kong Pharmaceutical Regulatory Centre and subsequent key tasks.

On October 17, Director Huang Guo of the China Drug Administration met with Hong Kong Medical and Health Bureau Secretary Lu Chongmao and Director of Health Lam Man-kin and his entourage in Beijing. The two sides had in-depth exchanges on topics such as further strengthening cooperation between the Mainland and Hong Kong in drug supervision and supporting Hong Kong's drug regulatory capacity building. Lu Chung-mau said that the Hong Kong Drug Supervisory Authority is promoting the implementation of the Hong Kong Special Administrative Region's first five-year plan, comprehensively deepening pharmaceutical supervision reform, and will maintain close communication with the China Drug Administration in the future to help the high-quality development of the pharmaceutical industry. Lin Wenjian explained the situation of the upcoming Hong Kong Pharmaceutical Regulatory Centre and subsequent key tasks.